Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy - PubMed (original) (raw)
Review
Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy
Jeenah Park et al. Epigenomics. 2015.
Abstract
Understanding the contribution of dysregulated gene silencing to epigenomic alterations in cancer development provides the rationale for the use of epigenetic modulators, such as histone deacetylase (HDAC) inhibitors, in cancer therapy. HDAC inhibitors have been approved as single agents for cutaneous and peripheral T-cell lymphoma and have shown promising activity in reversing therapy resistance in other tumor types. The effects of HDAC inhibitors on immune modulation have created a recent interest in their potential role in immunotherapy. This review describes the current understanding on integrating HDAC inhibitors into various immunotherapeutic approaches, such as cancer vaccines, adoptive T-cell transfer and immune checkpoint inhibitors. Furthermore, it summarizes promising treatment strategies in epigenetic immune priming from clinical trials that are currently underway.
Keywords: HDAC inhibitors; adoptive T-cell transfer; cancer; epigenetics; immune checkpoint inhibitors; immune response; immunotherapy; vaccines.
Similar articles
- Epigenetic modulation in cancer immunotherapy.
Gallagher SJ, Shklovskaya E, Hersey P. Gallagher SJ, et al. Curr Opin Pharmacol. 2017 Aug;35:48-56. doi: 10.1016/j.coph.2017.05.006. Epub 2017 Jun 10. Curr Opin Pharmacol. 2017. PMID: 28609681 Review. - HDAC inhibitors as epigenetic regulators for cancer immunotherapy.
Conte M, De Palma R, Altucci L. Conte M, et al. Int J Biochem Cell Biol. 2018 May;98:65-74. doi: 10.1016/j.biocel.2018.03.004. Epub 2018 Mar 10. Int J Biochem Cell Biol. 2018. PMID: 29535070 Review. - Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors.
Terranova-Barberio M, Thomas S, Munster PN. Terranova-Barberio M, et al. Immunotherapy. 2016 Jun;8(6):705-19. doi: 10.2217/imt-2016-0014. Immunotherapy. 2016. PMID: 27197539 Free PMC article. Review. - Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy.
Mazzone R, Zwergel C, Mai A, Valente S. Mazzone R, et al. Clin Epigenetics. 2017 May 30;9:59. doi: 10.1186/s13148-017-0358-y. eCollection 2017. Clin Epigenetics. 2017. PMID: 28572863 Free PMC article. Review. - Epigenetics and immunotherapy: The current state of play.
Dunn J, Rao S. Dunn J, et al. Mol Immunol. 2017 Jul;87:227-239. doi: 10.1016/j.molimm.2017.04.012. Epub 2017 May 14. Mol Immunol. 2017. PMID: 28511092 Review.
Cited by
- Applications of cell therapy in the treatment of virus-associated cancers.
Toner K, McCann CD, Bollard CM. Toner K, et al. Nat Rev Clin Oncol. 2024 Oct;21(10):709-724. doi: 10.1038/s41571-024-00930-x. Epub 2024 Aug 19. Nat Rev Clin Oncol. 2024. PMID: 39160243 Review. - Destabilizing the genome as a therapeutic strategy to enhance response to immune checkpoint blockade: a systematic review of clinical trials evidence from solid and hematological tumors.
Alotaibi F, Alshammari K, Alotaibi BA, Alsaab H. Alotaibi F, et al. Front Pharmacol. 2024 Jan 9;14:1280591. doi: 10.3389/fphar.2023.1280591. eCollection 2023. Front Pharmacol. 2024. PMID: 38264532 Free PMC article. - Epigenetic Perspective of Immunotherapy for Cancers.
Keshari S, Barrodia P, Singh AK. Keshari S, et al. Cells. 2023 Jan 19;12(3):365. doi: 10.3390/cells12030365. Cells. 2023. PMID: 36766706 Free PMC article. Review. - Comprehensive analysis of the clinical significance, immune infiltration, and biological role of MARCH ligases in HCC.
Cao J, Tu DY, Zhou J, Jiang GQ, Jin SJ, Su BB, Tang H, Tang YH, Wang AQ, Wang Q, Liu RJ, Zhang C, Bai DS. Cao J, et al. Front Immunol. 2022 Oct 3;13:997265. doi: 10.3389/fimmu.2022.997265. eCollection 2022. Front Immunol. 2022. PMID: 36263042 Free PMC article. - Targeting Histone Epigenetic Modifications and DNA Damage Responses in Synthetic Lethality Strategies in Cancer?
Lazo PA. Lazo PA. Cancers (Basel). 2022 Aug 22;14(16):4050. doi: 10.3390/cancers14164050. Cancers (Basel). 2022. PMID: 36011043 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources